MDxHealth FY26 H1 net loss widens 18% to $19.17 million; revenue rises 14% to $51.11 million
MDXH•Margins and business update
Gross profit rose 7% to $32.56 million; gross margin fell 4.2 percentage points to 63.7% on test mix.
Resolve UTI business was discontinued by June 30, 2026; August direct placement raised $20 million at $0.45 per share.
First-half results and profitability
MDxHealth posted revenue of $51.11 million for the six months ended June 30, 2026, up 14%.
Operating loss more than doubled to $13.26 million as operating expenses climbed 25% to $45.82 million.
Net loss from continuing operations widened 18% to $19.17 million; loss per share from continuing operations deepened to $0.37.
